Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Using Submyeloablative DOsing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors

NCT00836628 is registered in ClinicalTrials.gov with Ann & Robert H Lurie Children's Hospital of Chicago as lead sponsor.

NCT NCT00836628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Using Submyeloablative DOsing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Phase
Phase 1
Overall status
Withdrawn
Start date
July 31, 2008
Completion date
October 31, 2010
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory brain tumors